INTRODUCTION
============

Microsporidia has emerged in recent years as an opportunistic infectious agent with a ubiquitous distribution.[@b1-cln_66p1171]-[@b4-cln_66p1171] The clinical manifestations of this infection vary widely, from none (asymptomatic) to non-bloody watery diarrhea, abdominal cramps, weight loss, and disseminated disease, especially in immunosuppressed subjects.[@b2-cln_66p1171]-[@b4-cln_66p1171]

This parasitological disease primarily affects immunosuppressed patients,[@b1-cln_66p1171]-[@b4-cln_66p1171] particularly those with human immunodeficiency virus (HIV), malignancies and diabetes mellitus, as well as patients post heart-lung, liver, and renal transplantations.[@b1-cln_66p1171],[@b2-cln_66p1171] In addition, this infection also occurs in patients undergoing immunosuppressive drug treatment.[@b2-cln_66p1171],[@b4-cln_66p1171]

In fact, patients with rheumatic diseases who are taking disease-modifying anti-rheumatic drugs (DMARD) and anti-tumor necrosis factor (TNF) therapy have a high risk for general infections,[@b5-cln_66p1171]-[@b7-cln_66p1171] including intestinal pathogenic parasite infestations such as *Strongyloides stercoralis*.[@b8-cln_66p1171],[@b9-cln_66p1171] However, to our knowledge, there are no data regarding the risk of microsporidiosis in these patients.[@b10-cln_66p1171]-[@b13-cln_66p1171]

Therefore, the objective of this study was to evaluate the frequency and clinical significance of microsporidiosis in patients with rheumatic diseases who are undergoing anti-TNF/DMARD treatment compared to an age- and socio-economic condition-matched healthy population.

MATERIALS AND METHODS
=====================

We evaluated 89 consecutive patients at our hospital who were diagnosed with rheumatoid arthritis (RA) (American College of Rheumatology criteria),[@b14-cln_66p1171] ankylosing spondylitis (AS) (New York criteria),[@b15-cln_66p1171] or psoriatic arthritis (PsA) (European spondyloarthropathy Study Group -- ESSG criteria and Moll and Wright classification).[@b16-cln_66p1171] All patients were undergoing anti-TNF therapy (adalimumab, etanercept, or infliximab) combined with DMARDs. The control group included 92 healthy employees of our hospital who were matched by age and socio-economic status. Prior to this study, no specific routine existed in our Infusion Center with regard to stool examination for parasites and fecal leukocytes before anti-TNF therapy. The prophylactic use of anti-helminthic drugs was recommended for patients under concomitant glucocorticoid therapy.

This study was approved by the local ethics committee, and informed consent was obtained from each participant or his or her legal guardian.

Demographic data, the number of school years attended, and the socio-economic status (according to *Associação Brasileira dos Institutos de Pesquisa de Mercados*)[@b17-cln_66p1171] were recorded. Background information and parasitosis symptoms in patients and control participants were acquired via interview and included the following: general (loss of appetite, weight loss, and adynamia), gastrointestinal (abdominal pain, abdominal distension, flatulence, diarrhea, dysentery, tenesmus, obstipation, nausea, vomiting, hematochezia, and worm elimination), cutaneous (exanthema), and pulmonary manifestations (wheezing, thoracic pain, and hemoptysis).

Disease activity and laboratory evaluation of rheumatic diseases
----------------------------------------------------------------

Disease activity was evaluated by the following: the duration of morning stiffness, the number of swollen and/or painful joints, and the disease activity score (DAS28) for RA patients[@b18-cln_66p1171] and the number of swollen and/or painful joints and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)[@b19-cln_66p1171] for AS and PsA patients.

The laboratory parameters assessed included the erythrocyte sedimentation rate (ESR) according to Westergreen (mm/^1st^ hour) and C-reactive protein (CRP) level determined by nephelometry (mg/L). Data concerning current treatment with prednisone, DMARDs, anti-TNF and immunosuppressive drugs (methotrexate, azathioprine, leflunomide, chloroquine, sulfasalazine and/or cyclosporine) were collected.

Parasitological assessment
--------------------------

Three stool samples were collected from rheumatic disease patients and control subjects on different days and placed into plastic vials without preservatives. The stool samples were microscopically analyzed for the detection of protozoan oocysts, cysts, helminth eggs, and larvae by a qualified technician blinded to the groups using the techniques described by Faust et al, Rugai and Lutz (modified), and Hoffman, Pons and Janer.[@b20-cln_66p1171]

Microsporidia positivity was defined as the isolation of at least one parasite using the GRAM-Chromotrope[@b21-cln_66p1171] technique.

Intestinal coccidia were evaluated by the GRAM-Chromotrope[@b21-cln_66p1171] technique; Leishman staining[@b22-cln_66p1171] was used to identify *Blastocystis hominis* and fecal leukocytes; the Kinyoun procedure[@b23-cln_66p1171] and capture enzyme-linked immunosorbent assay (capture ELISA) were used to detect *Cryptosporidium sp*., *Cyclospora cayetanensis,* and *Isospora belli;* and Kato-Katz was used to detect *Schistosoma mansoni*.[@b24-cln_66p1171] Coproculture was also performed using SS agar, MacConkey agar or Karmali plate agar.[@b25-cln_66p1171]

*Giardia lamblia, Strongyloides stercoralis, Ancilostoma duodenali, Ascaris lumbricoides, Entamoeba histolytica, Microsporidia* (positive stool leukocytes), *Entamoeba dispar, Dientamoeba fragilis, Cryptosporidium parvum, Cyclospora cayetanensis, Isospora belli,* and *Blastocystis hominis* (positive stool leukocytes) were defined as pathogenic parasites in immunocompromised patients.[@b1-cln_66p1171] All participants with positive pathogenic parasites were treated with the appropriate recommended antiparasitic drugs.[@b26-cln_66p1171]

Statistical analysis
--------------------

Results are presented as the mean ± standard deviation or the median (range) for continuous variables and the number (%) for categorical variables. Continuous variables were compared using the *t* test and the Mann Whitney test to evaluate differences between patients with and without intestinal microsporidia and other parasitoses. For categorical variables, differences in proportions were assessed by Fisher\'s exact test. For all statistical tests, significance was set at a *p*-value \<0.05.

RESULTS
=======

A total of 89 patients with rheumatic diseases (47 RA, 31 AS and 11 PsA) and 92 healthy control subjects were included in this study. The two groups were comparable with regard to the mean current age (47.2±10.9 *vs.* 43.8±14.3 years, respectively; *p* = 0.094), percentage who were Caucasian (80 *vs.* 73%, respectively; *p* = 0.3) and socio-economic distribution, with a similar predominance of the middle and lowest Brazilian socio-economic classes (C, D or E)[@b17-cln_66p1171] based on scholarity and ownership of household items (84 *vs.* 82%, respectively; *p* = 0.7). There were a greater proportion of females in the control group than in the patient group (93 *vs.* 62%, respectively; *p*\<0.0001). The mean disease duration for all patients was 15.5±8.6 years.

Intestinal parasites
--------------------

The overall frequency of pathogenic parasites was similar in both the patient and control groups (63 *vs.* 58%, respectively; *p* = 0.54). Positive tests for microsporidia were significantly higher in all types of rheumatic disease patients compared with the control subjects (38 *vs.* 4%, respectively; *p*\<0.0001), and microsporidia plus positive fecal leukocytes were also more frequently detected in patients than in control subjects (31 *vs.* 4%, respectively; *p*\<0.0001). Of note, 81.6% of the positive microsporidia patients had concomitant fecal leukocytes. In contrast, no differences were detected for other pathogenic parasites (*Entamoeba histolytica/dispar, Dientamoeba fragilis, Giardia lamblia, Cryptosporidium parvum, Cyclospora cayetanensis, Isospora belli, Ancilostoma duodenale, Ascaris lumbricoides,* and *Blastocystis hominis* with leukocytes) and non-pathogenic parasites (*Endolimax nana, Entamoeba coli,* and *Entamoeba hartmanni*) (*p*\>0.05; [Table 1](#t1-cln_66p1171){ref-type="table"}). Among the 28 patients with microsporidia and positive stool leukocytes, 36% had other concomitant pathogenic parasites, particularly *Blastocystis hominis* \[8/28 (29%) patients\]; however, no association of microsporidia and *Blatocystis hominis* was observed (*p* = 0.28). Regarding the prevalence of pathogenic parasites in each disease compared to the control group, microsporidiosis was higher in RA (32 *vs.* 4%, respectively; *p*\<0.0001), AS (45 *vs.* 4%, respectively; *p*\<0.0001) and PsA patients (40 *vs.* 4%, respectively; *p*\<0.0001). Moreover, there were no statistical differences in microsporidia positivity between the specific diseases (RA *vs.* AS and PsA; AS *vs.* PsA; all *p*\>0.05). *Giardia lamblia* was significantly more common in AS patients *vs.* control subjects (10% *vs.* 0%, respectively; *p* = 0.0149), whereas no differences were observed for the other pathogenic parasites (*p*\>0.05).

Disease activity parameters at the study onset were alike in patients with and without microsporidia infections for all diseases (RA, AS, and PsA) (*p*\>0.05). The analysis of the duration of anti-TNF/DMARD therapy showed no statistical difference between patients with and without microsporidia infection (*p* = 0.55). The frequencies of glucocorticoid use in patients with and without microsporidiosis \[44% (95% IC 0.27-0.62) *vs.* 64% (95% IC 0.49-0.76); *p* = 0.08\] were alike, as was the number of DMARDs used ([Table 2](#t2-cln_66p1171){ref-type="table"}).

No differences were detected in the frequencies of other infections that required antibiotic therapy in patients with and without microsporidiosis, such as acute lower respiratory infection (2.9 *vs.* 14.5%, respectively; *p* = 0.14), urinary tract infection (29.4 *vs.* 30.9%, respectively; *p* = 1.0) cutaneous infection (20.6 *vs.* 23.6%, respectively; *p* = 0.8) and tuberculosis (2.9 *vs.* 1.8%, respectively; *p* = 1.0).

The comparison of rheumatic disease patients with and without microsporidiosis revealed that 85.4% of the patients had gastrointestinal symptoms such as diarrhea (19%), abdominal pain (22%), and weight loss (11%), but these symptoms occurred just as frequently in patients with and without this infection (*p*\>0.05). Other signs and symptoms related to parasitoses were also comparable in the two groups, with the exception of abdominal distension (*p* = 0.013) and adynamia (*p* = 0.009), both of which occurred less often in patients with microsporidiosis ([Table 3](#t3-cln_66p1171){ref-type="table"}). No patient or control group had a disseminated infection.

DISCUSSION
==========

This study is the first to identify a high frequency of microsporidia infections associated with intestinal mucosa disruption in rheumatic disease patients undergoing anti-TNF and DMARD therapies.

The study design has several advantages, including the inclusion of patients with well-established rheumatic disease criteria.[@b14-cln_66p1171]-[@b16-cln_66p1171] In addition, the Gram-Chromotrope stain methodology applied in this study is considered to be one of the most specific detection techniques with the best sensitivity for detecting microsporidia in fluids, including feces.[@b2-cln_66p1171] Moreover, external factors such as socio-economic conditions may influence parasitosis prevalence. For example, the frequency of microsporidia in HIV-infected patients was higher in Venezuela (13.6%), an underdeveloped country, than in Italy (1.8%).[@b27-cln_66p1171]-[@b28-cln_66p1171] This potential bias was greatly reduced by the matching of our patients with a control group with the same socio-financial distribution. One limitation of our study was the absence of a control group of rheumatic disease patients treated only with DMARDs, due to the impossibility of achieving an adequate matching for disease duration and severity in these patients. In fact, anti-TNF therapy is now being indicated very early for patients with these diseases. There are, however, no data on the frequency of microsporidia infection in rheumatic disease patients without anti-TNF therapy.

Microsporidia has emerged as an important cause of infectious complications in severely immunocompromised patients with HIV, recipients of solid organ transplant and patients with hematological malignancies.[@b1-cln_66p1171]-[@b3-cln_66p1171] Cell-mediated immunity appears to be critical for protection against microsporidia through the T helper cell 1 (Th1) cytokine response.[@b3-cln_66p1171] The importance of a Th1 response in the resistance to microsporidial infection has been demonstrated by *in vitro* studies showing that knockout animals for Th1 cytokines such as interferon and interleukin-12 could not clear microsporidia infections.[@b29-cln_66p1171] In fact, more severe microsporidia infections were observed in HIV-infected patients with declining CD4+ and CD8+ T-cell numbers.[@b29-cln_66p1171] Accordingly, the inhibition of TNF-alpha, a cytokine well known to be related to the Th1 response,[@b30-cln_66p1171] could possibly facilitate the microsporidia infestation observed in the present study. Moreover, experimental studies have reported a decrease in the specific protective IgG against microsporidia in animals treated with immunosuppressive drugs.[@b31-cln_66p1171] We have confirmed that microsporidia infestation is more prevalent in immunosuppressed patients[@b1-cln_66p1171]-[@b4-cln_66p1171] and have now extended this observation to rheumatic disease patients undergoing anti-TNF/DMARD treatment.

Microsporidiosis and intestinal parasitosis may present with diverse clinical manifestations, depending on the host immune status and the microsporidium species.[@b1-cln_66p1171]-[@b4-cln_66p1171] Diarrhea and wasting syndromes are the most common complaints;[@b1-cln_66p1171]-[@b4-cln_66p1171] however, these parasite infections can be asymptomatic. In fact, the parasitosis in our study was frequently associated with gastrointestinal manifestations and concomitant stool leukocytes, indicating a possible intestinal mucosa disruption,[@b32-cln_66p1171] which is a known risk for intestinal dissemination.[@b33-cln_66p1171]

Infection is a major co-morbidity in rheumatic conditions, and therapies such as conventional DMARDs and anti-TNF are known to enhance the risk of infection.[@b34-cln_66p1171],[@b35-cln_66p1171] In this regard, previous reports have suggested that susceptibility to infection may be distinct in different underlying rheumatic diseases. The main explanation for this finding seems to be a disease-associated genetic background and immunosuppressive therapy.[@b36-cln_66p1171],[@b37-cln_66p1171] However, in the present study, no difference was observed in microsporidiosis frequency between the specific rheumatic diseases, suggesting that anti-TNF/DMARD treatment is a more relevant risk factor for this infestation than is the specific rheumatic disease itself.

We have identified microsporidiosis to be a frequent infection that is associated with mucosal lesions in patients undergoing concomitant anti-TNF/DMARD treatment. This finding supports the notion that the recommendation for the prophylactic use of anti-helminthic drugs in patients on glucocorticoid therapy could be extended to those initiating anti-TNF therapy.
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###### 

Intestinal parasites in rheumatic disease patients undergoing anti-TNF/DMARD therapies and healthy controls.

  Intestinal parasites                      Rheumatic disease patients (n = 89)   Control subjects (n = 92)   *p*-value
  ----------------------------------------- ------------------------------------- --------------------------- -----------
  **Pathogenic parasites**                                                                                    
      Microsporidia                         34 (38)                               4 (4)                       \<0.0001
      Microsporidia with leukocytes         28 (31)                               4 (4)                       \<0.0001
  * Entamoeba histolytica/dispar*           0 (0)                                 4 (4)                       0.12
  * Dientamoeba fragilis*                   3 (3)                                 0 (0)                       0.12
  * Giardia lamblia*                        3 (3)                                 0 (0)                       0.12
  * Strongyloides stercoralis*              3 (3)                                 2 (2)                       0.68
  * Cryptosporidium parvum*                 3 (3)                                 5 (5)                       0.72
  * Cyclospora cayetanensis*                0 (0)                                 0 (0)                       1.0
  * Isospora belli*                         0 (0)                                 0 (0)                       1.0
  * Ancilostoma duodenale*                  1 (1)                                 0 (0)                       0.49
  * Ascaris lumbricoides*                   0 (0)                                 0 (0)                       1.0
  * Blastocystis hominis* with leukocytes   46 (52)                               42 (46)                     0.46
  **Non-pathogenic parasites**                                                                                
  * Endolimax nana*                         17 (19)                               25 (27)                     0.22
  * Entamoeba coli*                         6 (7)                                 12 (13)                     0.21
  * Entamoeba hartmanni*                    1 (1)                                 1 (1)                       0.5

Results are presented as n (%); DMARDs - disease-modifying anti-rheumatic drugs.

###### 

Disease activity parameters and treatments in patients with rheumatic diseases undergoing anti-TNF and DMARD therapies with and without microsporidia infection.

  Parameters                                         Patients with microsporidia (n = 34)   Patients without microsporidia (n = 55)   *p*-value
  -------------------------------------------------- -------------------------------------- ----------------------------------------- -----------
  **Rheumatoid arthritis (n = 47)**                                                                                                   
      Morning stiffness, minutes                     13±17.9                                26.9±43.2                                 0.24
      Number of painful joints                       6.5±5.8                                11±10                                     0.12
      Number of swollen joints                       4.8±5.1                                5.1±4.1                                   0.83
      DAS28                                          3.8±1.6                                4.6±1.3                                   0.10
      ESR, mm/1^st^ hour                             26.6±26.1                              27.1±15.5                                 0.94
      CRP, mg/L                                      8.49±9.5                               15.4±17.9                                 0.19
  **Ankylosing spondylitis (n = 31)**                                                                                                 
      Number of painful joints                       5.6±13.4                               3.6±4.2                                   0.59
      Number of swollen joints                       1.4±1.4                                1.7±2.3                                   0.68
      BASDAI                                         3.48±2.01                              3.47±2.43                                 0.99
      ESR, mm/1^st^ hour                             23±27                                  14±16                                     0.27
      CRP, mg/L                                      12.6±14.5                              13.2±21.1                                 0.94
  **Psoriatic arthritis (n = 11)**                                                                                                    
      Morning stiffness (minutes)                    0 (0-20)                               17.5 (0-120)                              0.14
      Number of painful joints                       5 (0-8)                                3.5 (0-12)                                0.93
      Number of swollen joints                       1 (0-2)                                1 (0-2)                                   0.77
      BASDAI                                         2.33 (0-6.98)                          4.06 (0.27-5.16)                          0.48
      ESR, mm/1^st^ hour                             11.5 (3-76)                            23(1-46)                                  0.73
      CRP, mg/L                                      2 (0.2-19.6)                           6.8 (1.5-32.5)                            0.55
  **Rheumatic patients treated (n = 89)**                                                                                             
      Anti-TNF and DMARD therapy duration (months)   15±11.7                                13.6±9.7                                  0.55
      Glucocorticoid use                             15 (44)                                35 (64)                                   0.08
      Methotrexate use                               26 (76)                                33 (60)                                   0.17
      Number of DMARDs                               1.1±0.7                                0.9±0.7                                   0.33

###### 

Clinical manifestations in patients with rheumatic diseases undergoing anti-TNF and DMARD therapies with and without microsporidia infection.

  Clinical manifestations        Patients with microsporidia (n = 34)   Patients without microsporidia (n = 55)   *p*-value
  ------------------------------ -------------------------------------- ----------------------------------------- -----------
  Abdominal pain                 10 (29)                                10 (18)                                   0.296
  Diarrhea                       10 (29)                                7 (13)                                    0.094
  Weight loss                    2 (6)                                  8 (15)                                    0.306
  Nausea                         8 (24)                                 14 (25)                                   1.0
  Vomit                          6 (18)                                 8 (15)                                    0.768
  Flatulence                     6 (18)                                 19 (35)                                   0.096
  Dysentery                      2 (6)                                  0 (0)                                     0.143
  Tenesmus                       0 (0)                                  4 (7)                                     0.294
  Obstipation                    6 (18)                                 9 (16)                                    1.0
  Loss of appetite               7 (21)                                 6 (11)                                    0.231
  Hematochezia                   2 (6)                                  5 (9)                                     0.704
  Worm elimination               0 (0)                                  5 (9)                                     0.152
  Wheezing                       8 (24)                                 5 (9)                                     0.072
  Thoracic pain                  8 (24)                                 6 (11)                                    0.139
  Hemoptysis                     2 (6)                                  2 (4)                                     0.635
  Exanthema                      2 (6)                                  10 (18)                                   0.121
  Abdominal distension           2 (6)                                  15 (27)                                   0.013
  Adynamia                       11 (32)                                34 (62)                                   0.009
  Any gastrointestinal symptom   29 (85)                                47 (85)                                   1.0
  Systemic dissemination         0 (0)                                  0 (0)                                     1.0

Results are presented as n (%); DMARDs - disease-modifying anti-rheumatic drugs.
